Related Experiment Videos
[Changes in lipoprotein(a) after heart transplantation]
L Almenar1, S Martí, M Palencia
1Servicio de Cardiología, Hospital Universitario La Fe. Valencia.
Revista Espanola De Cardiologia
|September 1, 1995
Summary
Lipoprotein (a) levels initially rise after heart transplant, then gradually decrease. These changes are not associated with common immunosuppressive drugs like cyclosporine, azathioprine, or deflazacort.
Area of Science:
- Cardiology
- Transplantation Immunology
- Lipid Metabolism
Background:
- Lipoprotein (a) [Lp(a)] is an independent risk factor for cardiovascular disease.
- Understanding Lp(a) dynamics post-heart transplant is crucial for patient management.
- Immunosuppressive therapy can influence lipid profiles in transplant recipients.
Purpose of the Study:
- To investigate the temporal changes in lipoprotein (a) levels following heart transplantation.
- To explore the potential correlation between post-transplant Lp(a) concentrations and standard immunosuppressive medications.
Main Methods:
- A cohort of 17 patients undergoing heart transplant without pre-existing dyslipidemia or dysglycemia was studied.
- Lp(a) levels were measured before transplantation and at 1, 2, 4, and 6 months post-transplant.
- Patients with post-transplant metabolic alterations (beyond the first week) or concurrent illnesses were excluded.
Main Results:
- A transient increase in Lp(a) was observed in the first month post-transplant, followed by a progressive decrease.
- Significant reduction in Lp(a) was noted at 6 months compared to pre-transplant levels.
- No significant correlation was found between Lp(a) levels and dosages of cyclosporine, azathioprine, or deflazacort.
Conclusions:
- Lipoprotein (a) levels exhibit a dynamic pattern after heart transplantation, increasing initially and then declining.
- The observed changes in Lp(a) are independent of the commonly used immunosuppressive drug regimens in heart transplant recipients.